Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1990-08-02
1993-02-23
Cashion, Jr., Merrell C.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 13, 514 14, 514 15, 514 21, 530324, 530325, 530326, 530327, A61K 3702, C07K 706, C07K 708, C07K 710
Patent
active
051890208
ABSTRACT:
A partially purified omega conotoxin binding protein is disclosed. The protein, either in partially purified form or in a synaptosomal preparation, is useful in identifying compounds for use in reducing neuronal damage related to an ischemic condition, such as stroke, in a human patient.
REFERENCES:
patent: 4447356 (1984-05-01), Olivera et al.
patent: 4925664 (1991-05-01), Jackson et al.
patent: 4950739 (1990-08-01), Cherksey et al.
Hamilton et al., Report 1989-Govt. Rep. Announce. Index (US), vol. 89 (22) p. 173 entry #960328 (1989).
Govoni et al., Minerva Med. vol. 77 (24) pp. 1053-1058 (1986) (abstract).
Iida et al., Jpn. Heart 3, vol. 31 (4) p. 536 (1990).
Mossakowski et al. Neuropat. Pol., vol. 25 (4) pp. 439-450 (1987).
Shapira et al., Brain Res., vol. 523 (2) pp. 291-294 (1990).
Choi, D. W., "Calcium-mediated neurotoxicity: relationship to specific channel types and role in ischemic damage" TINS, vol. 11 (10) pp. 465-469 (1988).
Bean, B. P., Annu. Rev. Physiol. 51:367-384 (1989).
Greenberg, D. A., Curr. Neurol. 6:91-121 (1986).
Hossmann, K.-A, "Calcium antagonists for the treatment of brain ischemia: A critical appraisal".
Marqueze, Beatrice, et al., Molecular Pharmacology, 34:87-90 (1988).
Vibulsreth, S., et al., Stroke 18:210-216 (1987).
Ahmad, S., et al., Brain Research, 453:247-256 (1988).
Anderson, A. J., et al., Neuroscience Letts., 82:177-180 (1987).
Bennett, J. P. et al., Neutransmitter Receptor Binding, pp. 61-89 Raven Press, NY (1983).
Gray, W. R., et al., Ann. Rev. Biochem., 57, pp. 655-700 (1988).
Haley, T., et al., Brit. J. Pharmacol., 23, pp. 12-15 (1957).
Kirino, T., Brain Research, 239, pp. 57-69 (1982).
McCleskey, E. W., et al., PNAS, 84, pp. 4327-4331 (1987).
Olivera, B., et al., Science, 230, pp. 1338-1343 (1985).
Pulsinelli, W. A., et al., Stroke, 10, pp. 267-272 (1979).
Sano, K., et al., Eur. J. Pharmacol., 141, pp. 235-141 (1987).
Tsien, R. W., et al., TINS, 11, pp. 431-438 (1988).
Van Reempts, J., et al., Acad. Anaesthesiolica Belge, 35, Suppl., pp. 209-218 (1984).
Wauquier, A., et al., Neuroscience and Biobehaviorial Reviews, 11, pp. 287-306 (1987).
Yamaguchi, T., Klatzo, I., in Cerebral ishemia, (Bes, A., Braquet, P., and Sisejo, B. K., eds.), Elsevier Sciences Publ., pp. 13-24 (1984).
Yamashiro, D., Int. J. Protein Peptide Res., 30, pp. 9-12 (1987).
Alps, B. J., et al., Neurology, 37, pp. 809-815 (1987).
Cruz, L. J., et al., Biochemistry, 26, pp. 820-824 (1987).
Grotta, J. C., et al., Ann. Neurol., 27, pp. 612-619 (1990).
Jones, O. T., et al., Science, 244, pp. 1189-1193 (1989).
Olivera, B. M., et al., Biochemistry, 26, pp. 2086-2090 (1987).
Simon, R. P., et al., Science, 226, pp. 850-852 (1984).
Onodera, H., et al., Stroke, 21, pp. 771-776 (1990).
Bitner Robert S.
Bowersox Stephen S.
Fox James A.
Miljanich George P.
Tsubokawa Makoto
Cashion Jr. Merrell C.
Dehlinger Peter J.
Neurex Corporation
Rozycki Andrew G.
LandOfFree
Method of reducing neuronal damage using omega conotoxin peptide does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of reducing neuronal damage using omega conotoxin peptide, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of reducing neuronal damage using omega conotoxin peptide will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2204842